Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children.
Marie-Louise Frémond,Mathieu Paul Rodero,Nadia Jeremiah,Alexandre Belot,Eric Jeziorski,Darragh Duffy,Didier Bessis,Guilhem Cros,Gillian I Rice,Bruno Charbit,Anne Hulin,Nihel Khoudour,Consuelo Modesto Caballero,Christine Bodemer,Monique Fabre,Laureline Berteloot,Muriel Le Bourgeois,Philippe Reix,Thierry Walzer,Despina Moshous,Stéphane Blanche,Alain Fischer,Brigitte Bader-Meunier,Fréderic Rieux-Laucat,Yanick Joseph Crow,Bénédicte Neven Journal of Allergy and Clinical Immunology(2016)
AI 理解论文
溯源树
样例